Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Actemra tocilizumab: Additional Phase III data

Additional data from the double-blind, placebo-controlled, international Phase III OPTION trial in 623

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE